144 related articles for article (PubMed ID: 36313914)
1. Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
EJIFCC; 2022 Aug; 33(2):166-174. PubMed ID: 36313914
[TBL] [Abstract][Full Text] [Related]
2. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
3. Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
Adv Lab Med; 2022 Jun; 3(2):167-174. PubMed ID: 37361867
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
5. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
Salvagno GL; Henry BM; di Piazza G; Pighi L; De Nitto S; Bragantini D; Gianfilippi GL; Lippi G
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34064509
[TBL] [Abstract][Full Text] [Related]
6. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
Salvagno GL; Pighi L; Henry BM; Valentini M; Tonin B; Bragantini D; Gianfilippi G; De Nitto S; Plebani M; Lippi G
Clin Chem Lab Med; 2023 Jun; 61(7):1343-1348. PubMed ID: 36722026
[TBL] [Abstract][Full Text] [Related]
7. The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay.
Salvagno GL; Henry BM; Lippi G
Int J Infect Dis; 2021 Oct; 111():65-67. PubMed ID: 34455083
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
9. Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization.
Salvagno GL; Lippi G
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746499
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose.
Gareayaghi N; Demirci M; Ozbey D; Dasdemir F; Dinc HO; Balkan II; Saribas S; Saltoglu N; Kocazeybek B
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298537
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
[TBL] [Abstract][Full Text] [Related]
12. Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers.
Salvagno GL; Henry BM; Pighi L; de NS; Lippi G
J Med Biochem; 2022 Apr; 41(2):199-203. PubMed ID: 35510202
[TBL] [Abstract][Full Text] [Related]
13. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
14. Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination.
Lippi G; Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G
Adv Lab Med; 2022 Mar; 3(1):39-50. PubMed ID: 37359438
[TBL] [Abstract][Full Text] [Related]
15. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
16. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
[TBL] [Abstract][Full Text] [Related]
17. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
18. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
[TBL] [Abstract][Full Text] [Related]
20. Changes in SARS-CoV-2 antibody titers 6 months after the booster dose of BNT162b2 COVID-19 vaccine among health care workers.
Mochizuki T; Hori T; Yano K; Ikari K; Okazaki K
Clin Exp Vaccine Res; 2023 Apr; 12(2):116-120. PubMed ID: 37214144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]